Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Recruiting 8Completed 5Unknown 4Not yet recruiting 3

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Other solid neoplasm 4

Conditions

Breast Neoplasms 1871Neoplasms 1257Colorectal Neoplasms 1057Carcinoma, Non-Small-Cell Lung 1012Stomach Neoplasms 802Carcinoma, Hepatocellular 785Lung Neoplasms 769Prostatic Neoplasms 697Pancreatic Neoplasms 577Rectal Neoplasms 449Ovarian Neoplasms 406Colonic Neoplasms 405Neoplasm Metastasis 403Uterine Cervical Neoplasms 400Recurrence 382Leukemia, Myeloid, Acute 372Esophageal Neoplasms 363Multiple Myeloma 339Lymphoma 335Head and Neck Neoplasms 330Melanoma 312Precursor Cell Lymphoblastic Leukemia-Lymphoma 292Brain Neoplasms 264Urinary Bladder Neoplasms 256Liver Neoplasms 225Nasopharyngeal Carcinoma 223Leukemia 218Lymphoma, Large B-Cell, Diffuse 216Polycystic Ovary Syndrome 210Squamous Cell Carcinoma of Head and Neck 205

Interventions

tislelizumab 1Sirolimus 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × Malignant Solid Tumors × Clear all
NCT06082557 2023-10-13

A Study to Observe and Evaluate the Safety and Efficacy of T60c Injection for Treatment of Advanced Solid Tumor Patients

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1/2 Unknown
62 enrolled
Other solid neoplasm

Malignant Solid Tumors

NCT05508620 2022-08-23

A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 1 Unknown
270 enrolled
Other solid neoplasm

Malignant Solid Tumors

NCT05441046 2022-07-06

Genakumab Alone and in Combination With Tislelizumab in Patients With Advanced Malignant Solid Tumors

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 1 Unknown
120 enrolled
Other solid neoplasm

Malignant Solid Tumors

NCT01694472 2015-12-22

Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors

Tianjin Medical University Cancer Institute and Hospital

Phase 1 Unknown
15 enrolled
Other solid neoplasm

Malignant Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡